Brentuximab Vedotin Approved for Classical HL

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

Source: CancerNetwork - April 10, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news